Drugs / BNT324
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06892548 | May 2025 → Sep 2028 expected | lung cancer | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05914116 | Aug 2023 → Dec 2027 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06953089 | Jul 2025 → Jun 2030 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07365995 | Apr 2026 → Feb 2031 expected | prostate carcinoma | BioNTech SE | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-24 | BioNTech SE | BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer biontech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT324 | “A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors” NCT05914116 ↗ |
| Known as | DB-1311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05914116 ↗ |
| Modality | Other / unclassified | “BNT324, a B7-H3 antibody-drug conjugate (ADC)” NCT06892548 ↗ |
| Route | Intravenous | “Administered I.V.(intravenous infusion)” NCT05914116 ↗ |